Meeting
2022 ASCO Annual Meeting
Early detection of cancer using cell-free DNA (cfDNA) size analysis on a multiplexed amplicon-based next-generation sequencing (NGS) platform.
Authors
Yukti Choudhury
Lucence Diagnostics, Singapore, Singapore
Yukti Choudhury , Pannapa Pinweha , Jonathan Poh , Jing Shan Lim , Min-Han Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3041)
DOI
10.1200/JCO.2022.40.16_suppl.3041
Abstract #
3041
Poster Bd #
33
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers.
First Author: Filip Janku
Poster
2024 ASCO Annual Meeting
High-sensitive multi-cancers early detection for 8 cancer types by cell-free DNA targeted methylation sequencing: A retrospective cohort study.
First Author: Huiyan Luo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Use of tumor-informed ctDNA across gastrointestinal cancers.
First Author: Matthew Reilley
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.
First Author: Khalid Jazieh